Cart
sales@molnova.com
[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]acetic acid
CAS No. 17969-20-9
[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]acetic acid ( 2-[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]ACETIC ACID )
Catalog No. M22256 CAS No. 17969-20-9
[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]acetic acid?is an anti-inflammatory thiazole.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 45 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 91 | In Stock |
|
| 25MG | 165 | In Stock |
|
| 50MG | 248 | In Stock |
|
| 100MG | 372 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]acetic acid
-
NoteResearch use only, not for human use.
-
Brief Description[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]acetic acid?is an anti-inflammatory thiazole.
-
Description[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]acetic acid?is an anti-inflammatory thiazole.
-
Synonyms2-[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]ACETIC ACID
-
PathwayOthers
-
TargetOther Targets
-
Recptoranti-inflammatory
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number17969-20-9
-
Formula Weight253.71
-
Molecular FormulaC11H8ClNO2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC(=O)Cc1c[s]c(n1)c2ccc([Cl])cc2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Glycerophosphocholin...
Glycerylphosphorylcholine is a natural choline compound found in the brain and in milk. It is also a parasympathomimetic acetylcholine precursor which may have a potential for the treatment of Alzheimer's disease and dementia.
-
Ephedrannin A
Ephedrannin A has Anti-melanogenesis activity. Ephedrannin A has anti-inflammatory activity.
-
56-Dimethylbenzimida...
Dimethylbenzimidazole is an intermediate in Riboflavin metabolism. Dimethylbenzimidazole is the second to last step for the synthesis of alpha-Ribazole.
